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Abstract
Skin-derived dendritic cells (DC) are potent antigen presenting cells with critical roles in both
adaptive immunity and tolerance to self. Skin DC carry antigens and constitutively migrate to the
skin draining lymph nodes (LN). In mice, Langerin-CD11b− dermal DC are a low-frequency,
heterogeneous, migratory DC subset that traffic to LN (Langerin-CD11b-migDC). Here, we build
on the observation that Langerin-CD11b− migDC are Fms-like tyrosine kinase 3 ligand (Flt3L)
dependent and strongly Flt3L responsive, which may relate them to classical DCs. Examination of
DC capture of FITC from painted skin, DC isolation from skin explant culture, and from the skin
of CCR7 knockout mice which accumulate migDC, demonstrate these cells are cutaneous
residents. Langerin-CD11b-Flt3L responsive DC are largely CD24(+) and CX3CR1low and can be
depleted from Zbtb46-DTR mice, suggesting classical DC lineage. Langerin-CD11bmigDC
present antigen with equal efficiency to other DC subsets ex vivo including classical CD8α cDC
and Langerin+CD103+ dermal DC. Finally, transcriptome analysis suggests a close relationship to
other skin DC, and a lineage relationship to other classical DC. This work demonstrates that
Langerin- CD11b− dermal DC, a previously overlooked cell subset, may be an important player in
the cutaneous immune environment.
INTRODUCTION
As the primary barrier between the body and the outside world, the skin is a unique immune
organ. The importance of cutaneous immunity is demonstrated several ways. First,
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tsuccessful vaccination strategies rely on delivery of vaccine antigens to the skin including
vaccinia (Liu et al., 2010) and dermally-delivered influenza (Kenney et al., 2004). Second,
innate immune adjuvants that act on the cutaneous immune network (imiquimod,
resiquimod) can lead to the regression of lentigo maligna and superficial spreading basal cell
carcinomas (Schon and Schon, 2008). Third, steady state immune surveillance is critical to
prevent skin cancers as evidenced by the markedly increased incidence of neoplasia
observed in renal transplant recipients maintained on immunosuppressive agents (Clark,
2010). Despite the immune-responsive nature of skin cancers and potential for skin resident
immune cells to mediate adaptive responses to cancer and infection, therapies have not been
generated to prevent skin cancer formation. Improved understanding of adaptive immunity
in the cutaneous environment is needed.
Adaptive cutaneous immunity depends on Dendritic Cells (DC) that abundantly populate the
skin and skin draining LN. DC are low-frequency hematopoietic cells, specialized at antigen
presentation. DC educate T cells to respond to tumor and microbial antigens, control the
developing immune response, and maintain long-term immune memory to tumors and
infections. In the non-inflamed state human skin contains 4 known phenotypically distinct
subsets of DC (Haniffa et al., 2012; Teunissen et al., 2012), while murine skin contains 5
(Henri et al., 2010). These DC continuously migrate from skin to the draining LN and are
collectively termed migratory (migDC). Given such phenotypic heterogeneity amongst skin
DC, increasing efforts are aimed at identifying their functional and developmental attributes
and correlating these with well-described DC subsets in other tissues.
Classical-DC are lymphoid and non-lymphoid DC that derive from pre-DC originating from
a common bone marrow precursor (Common DC Precursor). The term classical is used to
distinguish these populations from plasmacytoid DC (PDC) (Merad et al., 2013) and
monocyte-derived DC which develop in the setting of inflammation. Classical DC broadly
may be divided into CD11b+ and CD11b− populations. Classical DC that are LN and spleen
resident and are CD11b− also express CD8α and CD205 (termed CD8α+ cDC), while
CD11b+ LN and spleen resident DC lack expression of CD8α- (termed CD11b+ cDC). In
peripheral tissue such as skin CD11b− and CD11b+ may be additionally divided based on
other markers such as CD103 and Langerin.
In draining LNs, cell-surface expression of CD11c and MHCII is used to separate the 3
major DC groups: plasmacytoid DC, LN resident classical DC (cDC), and migratory DC
(migDC). MigDC include some DC of classical lineage that are CD11b− and CD11b+ such
as Langerin+CD103+CD11b− DC and Langerin-CD11b+ DC respectively (Ginhoux et al.,
2009). MigDC also include Langerhans cells (LC) of the epidermis, whose origin is distinct
and which are not seeded from pre-DC, but derive instead from radioresistant precursors
(Helft et al., 2010). Though an additional migratory population of CD11b− cells was
previously identified in skin (Langerin-CD11b-) (Henri et al., 2010), these cells have been
largely overlooked and incompletely characterized because they exist in low abundance in
other peripheral tissue such as the lung and mucosa, though they comprise a significant
fraction of DC from the skin.
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tSome DC are functionally specialized at cross-presentation, the major pathway to present
viral and tumor antigens. These DC have unique properties that make them attractive
cellular targets for vaccination (Poulin et al., 2010). When mature, they are superior to
cross-present exogenous antigens on MHC I, ingest dead or dying cells, and produce IL-12
in response to innate and T cell derived cues (Shortman and Heath, 2010; Yamazaki et al.,
2008). In skin, Langerin+ CD103+ DC cross-present antigens, and CD8α +CD11b− DC,
which also express the C-type lectin CD205 (CD8α DC), cross-present antigens in lymphoid
organs. In skin and other epithelial tissue, CD103+ DC, cross-present antigens from
cytolytic viruses and epithelial pathogens (Bedoui et al., 2009) including influenza (Helft et
al., 2012), herpes virus (Bedoui et al., 2009), and erosive candida (Igyarto et al., 2011).
Several lines of evidence suggest that other skin DC beyond Langerin+ CD103+ DC may
have an important role in priming to vaccines and pathogens. Langerin+ CD103+ DC are
not required in dermal vaccine administration (Flacher et al., 2012). Furthermore, residual
antigen presentation capacity to cutaneous pathogens including erosive candida (Igyarto et
al., 2011) and vaccinia (Seneschal et al., 2013) is observed in the absence of Langerin
+CD103+ DC. These data suggest that another DC subset may cross-present antigens locally
in the skin and skin-draining LN.
Flt3L, a DC hematopoietin, and its receptor (Flt3, FLK2) regulate classical DC homeostasis
of both DC in lymphoid organs and DC at, or arriving from, peripheral tissue (CD103+ DC
in skin and lungs) (Waskow et al., 2008, Liu et al., 2009). Migratory Langerin+ CD103+
DC, CD8α lymphoid resident cDC, and human BDCA3+ cross-presenting DC share
developmental dependence on Flt3L (Haniffa et al., 2012, Ginhoux et al., 2009). Flt3L
treatment biases cDC development to cross-presenting DC (Bozzacco et al., 2010). Flt3L
expansion of DC has helped identify very infrequent but functionally important DC at
epithelial sites- such as blood brain barrier (Anandasabapathy et al., 2011) and aortic intima
(Choi et al., 2011). However Flt3L dependence has not been used to characterize infrequent
DC in the skin or migDC in the skin draining LN.
Here we analyze the cutaneous residence, migratory properties, developmental dependence,
transcriptome, and functional properties of a cutaneous Langerin-CD11b− migratory DC
subset (abbreviated Langerin- CD11b− migDC). Our data suggest this subset is
heterogeneous but contains highly Flt3L-responsive DC with potent antigen presentation
capacity. We demonstrate Langerin-CD11b− migDC share many features with other
classical Flt3L-dependent DC.
RESULTS
Langerin-CD11b− migDC are Flt3L dependent
We examined the expansion of migDC in the skin draining LNs of mice in the presence and
absence of in vivo Flt3L treatment. MigDC can be gated as CD11cint and IAIE (MHCII)hi
and further divide into Langerin+ known DC subsets including Langerin+ CD103+ DC, and
Langerin+ CD103- DC (which includes Langerhans cells). Langerin- migDC subsets include
Langerin-CD11b+ DC and Langerin-CD11b-DC (Henri et al., 2010). (Figure 1A, and gating
in Figure S1A). In C57BL/6 mice (Figure 1A) and Langerin GFP mice (Figure 1B) treated
with Flt3L, we observed a major expansion of LN migDC within the Langerin-
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tcompartment, comprised of both CD11b+ and CD11b− cells. This was intriguing because
our lab and others have shown a parallel expansion of CD11b− (CD8α +) and CD11b+
(CD8α-) cDC in lymphoid tissue after Flt3L treatment (Bozzacco et al., 2010). LN DC
subsets numbers were quantitated from mice Flt3L treated, untreated, and knockout mice
(Figure 1C). Langerin-CD11b+ and Langerin-CD11b− subsets were expanded most
significantly by Flt3L treatment. Flt3L loss affected Langerin+CD103+ DC, and Langerin-
CD11b+ and Langerin-CD11b− subsets.
CD11b− migDC are skin resident and traffic to the skin draining LN
To ascertain if Langerin-CD11b− cells migrated to the LN from skin, or were a contaminant
from LN resident populations such as CD8α cDC, we examined skin explants in which DC
are directly isolated from skin. CD11b− cell were present and expanded with Flt3L in
“crawlout” DC isolation from skin (gating, Figure S1B). We established this in several
models- in Flt3L doxycycline-inducible mice (Manfra et al., 2003) (Figure 1D),
recombinant Flt3L-treated Langerin GFP mice (Figure 1E, S1B), recombinant Flt3L-treated
C57Bl/6 mice (Figure S1C), and Flt3L secreting B16 tumor treated mice (Figure S1D). In
cDC Flt3L creates bias to CD8α CD205+ cross-presenting cDC. Analysis of CD205+
expression on migDC explants revealed Langerin-CD11b− DC contained both CD205high
and CD205low cells in the steady state. However, a higher percentage of CD11b− cells are
CD205high after treatment with Flt3L (Figure 1F).
Skin migDC depend on CCR7 for migration to LN (Forster et al., 1999). To further validate
that Langerin-CD11b− cells in LN have migrated from the skin, we examined CCR7−/−
mice treated with Flt3L vs. untreated controls. Irrespective of Flt3L treatment, LNs from
CCR7 knockout mice lack cells within the CD11cintIAIEhi DC migratory gate (Figure 2 A,
upper panel). MigDC subsets including CD11b− cells preferentially accumulated in skin
explants and expanded with Flt3L locally in skin (Figure2A, lower panel). When FITC is
applied with a contact-sensitizing agent to the epidermis of mice, migDC rapidly transport
FITC from skin to skin draining LN. FITC label was present only in the IAIEhi migratory
cells (Figure 2B). Examination of FITC+ migDC vs. all migDC demonstrated an enhanced
representation of FITC+ Langerin-CD11b− cells during inflammation and FITC painting.
Several populations of DC transported FITC to the skin draining LN, yet a greater fraction
of Langerin-CD11b− and Langerin-CD11b+ DC subsets were present that labeled with
FITC when compared to all migDC after FITC painting (Figure 2B). These data suggest
Langerin-CD11b− DC like other migDC can transport FITC from the skin to the skin
draining LN. To visualize Langerin-CD11b− DC directly in skin immunofluorescence
staining was performed in Flt3L treated and untreated mice. LC were marked in the
epidermis (Langerin+ CD11b+ CD11c+). Contained within dermal CD11c+ cells, we
observed Langerin-CD11b+ DC, Langerin-CD11b− DC, and Langerin+CD11b− cells
(Figure 2C).
Langerin-CD11b− migDC are heterogenous but contain a Flt3L responsive CD24hi
CX3CR1low DC population
Given that CD205high and CD205low expressing cells were present in the steady state within
Langerin- CD11b− migDC, yet enhanced numbers of CD205high expressing cells were
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tnoted after Flt3L treatment, we speculated that the Langerin-CD11b− subset might be
heterogeneous in the steady-state. To address this we examined CD24 expression, an
additional marker for CD8α cDC, on migDC before and after Flt3L treatment. We observed
Flt3L treatment expands the percentage of Langerin-CD11b− cells expressing CD24 in the
LN from about 40% to almost 80% with a more modest and variable percentage expansion
in skin (Figure 3A, S1C−D). We also noted that in skin and LN an increase in the absolute
number of Langerin-CD11b-CD24+ cells occurred after Flt3L and a correspondingly higher
ratio of Langerin-CD11b-CD24+ cells in Flt3L treated vs. control mice (quantitation, S2).
An increased percentage of CD24+ cells after Flt3L was also observed on CD8α + cross-
presenting cDC in LN. Langerin+ DC subsets have high CD24 expression and CD11b+ DC
have lower CD24+ levels at baseline. In CD11b+ migDC, CD24+ percentage was not
dramatically altered after Flt3L treatment in LN and skin (Figure 3A and S1C–D). These
data suggest Flt3L expands CD24+ Langerin-CD11b− cells. In contrast, during FITC
painting in the presence of a pro-inflammatory contact-sensitizing agent we observe the
expanded CD11b− population is predominantly CD24low (Figure S1E).
To further investigate Langerin-CD11b− heterogeneity, we examined the expression of
CX3CR1 using CX3CR1-GFP reporter mice (Jung et al., 2000). The chemokine receptor
CX3CR1 (fractaline) is abundantly expressed on CD11b+ LN resident cDC and largely
absent from the majority of CD8α LN resident cDC, which helps to distinguish these 2
subsets (Figure 3B). The small fraction of CD8α+ DC which express CX3CR1, lack cDC
capacity for IL-12 secretion, cross-presentation of antigen, and resemble CD8α cDC (Bar-
On et al., 2010). After Flt3L treatment, CD8α+ CD24hi CX3CR1low cDC (red, upper)
remain well-distinguished from CD11b+ CD24low CX3CR1hi cDC (blue, upper) (Figure
3B). In the steady state Langerin-CD11b− cells are approximately 50% CD24high
CX3CR1low as compared to Langerin-CD11b+ migDC which were predominantly
CD24lowCX3CR1hi in the steady state (lower, left). After Flt3L, 70% of Langerin-CD11b−
migDC became CD24hi CX3CR1low suggesting Flt3L expands this population selectively
(lower, right). Collectively these data suggest in the steady state Langerin-CD11bcells are
heterogeneous but Flt3L selectively expands a CD24hi CX3CR1low subset, distinct from
CD11b+ CD24low CX3CR1hi migDC.
Langerin-CD11b− migDC, like other cDC, depend on the transcription factor Zbtb46
To further characterize Langerin-CD11b− cells we took advantage of recently generated
Zbtb46-diptheria toxin receptor (DTR) mice which allows specific depletion of cDC and
their precursors, but does not affect PDCs, monocytes, or macrophages (Meredith et al.,
2012a; Meredith et al., 2012b; Satpathy et al., 2012). At 24 and 48 hours post DT treatment
an overall gross reduction in total number of LN resident cDCs was observed as expected
(Figure 4A, gating S3A). MigDC were also rapidly depleted (Figure 4B). Langerin-CD11b−
cells were efficiently depleted along with other cDC in the LN (Figure 4B) and in skin (4C
and S3B) with few residual cells left. These data suggest Langerin-CD11b− cells are a
Zbtb46-expressing classical DC subset that shares the same origin as cDC.
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To further examine whether the Langerin-CD11b− subset could perform key DC functions
we sorted CD8α LN resident cDC and several migDC subsets from Langerin GFP mice
treated with Flt3L. We tested individual DC subsets (C57BL/6) in the mixed leukocyte
reaction (MLR) using T cells from BALB/c mice. All DC types could effectively stimulate
allogeneic T cells, including Langerin-CD11b− migDC (Figure 5A–B). Additionally we
sorted and cultured DC subsets with titrated doses of OVA protein and CD8+ −1 transgenic
T cells. Again Langerin-CD11b− DC were comparable to other LN resident and migDC
subsets at OVA-antigen presentation to CD8 T cells ex vivo (Figure 5C–D, gating and
representative flow data Figure S4). These data suggest Langerin-CD11b− migDC perform
equivalent antigen presentation of OVA to CD8+ T cells when compared to other DC,
including CD8α and CD103+ Langerin+ DC.
Langerin-CD11b− migDC relate closely to other skin DC and other cDC and express core
DC signature genes
To further address the relationship of individual migDC populations to each other and to
cDC in LN we performed transcriptome analysis. We also included two additional subsets of
LN DC in our analysis obtained from LPS treated mice: DC-SIGN+ monocyte-derived DC
and CD205+ DC (Cheong et al., 2010) and peritoneal macrophages. Using principal
component analysis (PCA) we identified four distinct clusters (data not shown): one cluster
was formed by migDC subsets including Langerin CD103+DC, Langerin-CD11b+DC, and
Langerin-CD11b− DC, consistent with prior work suggesting tissue DC cluster together
(Miller et al., 2012). Hierarchy analysis (dendrogram) (Figure 6A) revealed close
relatedness of cutaneous Langerin-CD11b+ and Langerin-CD11b− subsets to each other,
and to Langerin+CD103+ and CD8α cDC when compared against macrophages and LPS-
treated DC subsets.
Recent studies have defined a “core-DC gene signature” when comparing multiple cDC to
macrophages (Miller et al., 2012). By heat map analysis we analyzed the expression of
many of these previously defined core DC genes in our subsets, shown as a relative fold
expression against macrophages (Figure 6B). Many core DC genes including Flt3, Ccr7, and
Zbtb46 were upregulated in all DC subsets examined including Langerin-CD11b− migDC.
Heat map comparison of additional selected DC genes was also performed across all
populations (Figure 6C). These include Irf8, Clec9A, Ly75 (CD205, Dec205), Stat3,
Zbtb46, Flt3, and Ccr7. Irf8, a transcription factor necessary for CD8α (and its equivalents)
lineage development (Seillet et al., 2013), was observed at the highest expression intensity
in CD8α+ and Langerin+CD103+ and in CD205+ DC despite LPS treatment. CD11b−
migDC levels of Irf8 were intermediate but higher than in CD11b+ DC, DC-Sign+ LPS-
treated monocyte-derived DC, and macrophages.
DISCUSSION
This study characterizes a previously identified skin resident subset of immune cells (Henri
et al., 2010), that we now demonstrate are migDC sharing many properties to cDC including
Flt3L and Zbtb46 dependence. The current study builds on prior work in which Langerin-
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tCD11b− DC along with several other subsets were isolated from skin and skin draining LN
of mice. Previously Langerin-CD11b− DC were noted to share division and repopulation
kinetics along with other dermal DC such as Langerin+CD103+ DC suggesting a common
precursor (Henri et al., 2010), yet have been largely overlooked given the cross-presenting
properties of Langerin+CD103+ DC. Here we provide a dedicated characterization of
Langerin-CD11b− migDC based on developmental, phenotypic, and functional DC criteria
establishing these cells as a distinct DC subset by transcriptome analysis and relating them
to other Flt3Ldependent classical DC subsets, distinct from monocytes and macrophages.
We establish Langerin-CD11b− are heterogeneous in the steady state but contain a highly
Flt3L-dependent and responsive population. Markedly reduced dermal Langerin-CD11b+
and Langerin-CD11b− DC subsets were gated from LN in Flt3L−/− mice. Flt3L treatment
preferentially expanded Langerin-CD11b− and Langerin-CD11b+ dermal DC subsets in the
LN, and in the skin by crawlout explant. This may parallel spleen and BM where Flt3L
expanded DC consistently divide into CD11bhi DC subsets (CD8α-cDC equivalents) and
CD11blow CD24hi SIRP α low-intermediate (CD8α + cDC equivalents) (Naik et al., 2005).
Langerin-CD11b− Flt3L responsive DC, like classical CD8α +CD11b− cDC, are CD24+
and CX3CR1low and are efficiently depleted in DT-treated Zbtb46 DTR mice. Like other
migDC, we determine Langerin-CD11b− are CCR7 dependent, are skin residents by explant
and FITC painting, expand locally in the skin in response to Flt3L, and may be visualized in
the dermis. Langerhans cells are radio-resistant, do not express Flt3 (Ginhoux et al., 2012),
and were not anticipated to expand. These data suggest Langerin- DC comprise the majority
of the 14-fold Flt3L based CD11c+ expansion previously noted in dermis (Esche et al.,
1999). Though our study was conducted in mice, Flt3L dependence and Flt3L expansion of
local cutaneous DC subsets is of particular importance to the cancer vaccine arena as current
and prior translational efforts aim to deliver cancer antigens to DC after subcutaneous
administration of Flt3L.
We observed Langerin-CD11b− DC from mice treated with Flt3L performed allo-MLR and
cross-presentation to OVA at equal efficiency to LN resident cDC. This suggests an efficient
role in antigen presentation and bona fide DC function. This may be of significance to
priming against erosive candida and cytolytic viruses where residual T cell priming by DC
occurs even in the absence of Langerin+CD103+ dermal DC, yet no other DC subset in skin
has been identified as responsible for residual priming. However strictly ex vivo analysis of
DC function is somewhat limited by the fact that migDC mature in culture after leaving the
skin and distinct individual in vivo roles of cutaneous DC subsets are still incompletely
characterized. Current models of acute DC depletion (Langerin-DTR, CD11B-DTR,
Zbtb46-DTR, and CD11c-DTR) cannot selectively isolate Langerin-CD11b− migDC at this
time; therefore it will be difficult to immediately resolve their in vivo role in mediating
cutaneous immunity. It is possible that when licensed to prime, DC subset activity in the
skin could relate to specialization or non–redundant coverage of various pathogens.
Differing susceptibility of DC subsets to infection may permit discrete roles in antigen
presentation, as observed for tissue resident CD103+ DC vs. alveolar macrophages during
influenza infection (Helft et al., 2012).
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three dermal DC subsets are closely related at the transcriptome level to each other and may
suggest that tissue microenvironment impacts terminal DC differentiation. As such,
Langerin+CD103+ DC group more closely with other migDC than with their lymphoid
developmental and functional equivalents-CD8α cDC. Perhaps in the steady state tissue
resident migDC may act in concert. Intriguingly LN CD205+ cDC from LPS treated mice
cluster with LPS-treated DC such as DC-SIGN+ monocyte-derived DC than to cDC. The
dominant gene signatures relating these subsets in this context are likely related to LPS
treatment.
A lack of clarity surrounding the function and development of diverse DC subsets present in
the skin and skin draining LN has long hindered the development of vaccines and clinical
therapeutics to skin cancer. This work suggests the previously overlooked Langerin-CD11b−
DC subset contains a distinct, previously uncharacterized Flt3L-responsive migratory
population with many properties of cDC. As such, Langerin-CD11b− DC may serve as a
potential target of therapeutics aimed to enhance cutaneous immunity and as a mediator of
the cutaneous immune response.
METHODS
Tissue Harvest and DC Cell Preparation
“Flt3L-treated” mice were injected by the intraperitoneal (IP) route with endotoxin-free (<
0.0064 EU/mg), GMP grade, recombinant human Flt3L (Celldex) at 10µg/mouse/day,
diluted in sterile PBS vs. sterile PBS treated or untreated C57Bl/6 controls by IP injection.
“Tumor treated” 8–12 week C57BL/6 F or Langerin-GFP mice were administered 5 × 106
murine Flt3L-secreting B16 melanoma tumor cells by subcutaneous injection. Doxycycline-
inducible models of Flt3L induction have been previously characterized (Manfra et al,
2003). At 10–14 days of IP injection of Flt3L, approximately 10 mm tumor size, or after 8–
12 days of doxycycline addition to drinking water, mice were sacrificed. Skin-draining LNs
(inguinal, brachial, axillary, popliteal, and superficial cervical pooled) and spleen were
isolated from individual mice. LNs and spleen were added to Collagenase D (400 U/ml,
Roche) in Hanks’ Balanced Salt Buffer (Gibco) solution. LNs were teased apart and spleen
were injected with this solution using a 22–23 gauge needle attached to a 3 mL syringe, and
incubated for 25 minutes at 37°C (Steinman et al., 1979). After incubation 0.5M EDTA was
added to a final concentration of 10mM EDTA for disruption of DC:T cell complexes and
the sample was further incubated for 5 min at 37°C. For spleen cell preparation, ACK lysis
of red cells was performed. Undigested fibrous material was filtered through a 70 µm cell
strainer. Subsequent washed were performed with ice cold PBS with 2% fetal calf serum
(FCS). For crawlout assay, individual ears were harvested, washed in 70% EtOH and both
sides of ear halves were split dermal side down into R5-RPMI media with 10% FCS.
Crawlouts were harvested in 6 well plates (one ear per well) leading to some variability in
total cell counts across explants. At 72 hours cell suspensions were isolated and filtered. The
pellet was washed twice, and incubated in Fc block with 2% rat serum prior to cell surface
marker antibody staining.
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tMice—C57BL/6 mice (B6) were purchased from Taconic Labs or bred at Rockefeller
University. CCR7−/− mice were bred at Rockefeller after purchase from Jackson and are
described with respect to defects in the skin-derived DC migration (Martin-Fontecha et al.,
2008; Martin-Fontecha et al., 2003). Langerin-GFP mice were generously provided by
Bernard Malissen, bred as homozygotes at Rockefeller University, and have been previously
described (Kissenpfennig et al., 2005). CX3CR1-GFP mice were purchased from Jackson
and previously described (Jung et al., 2000). Zbtb46-DTR mice were generously provided
by Matthew Meredith and Michel Nussenzweig. Doxycycline-inducible Flt3L were kindly
provided by Sergio Lira. All mice were housed in specific pathogen–free conditions.
Protocols were approved by the Rockefeller University and Harvard University Animal Care
and Use Committees.
DC isolation—For allo-MLR, OVA presentation, and microarray RNA isolation DC
subsets were sorted from 5–10 pooled Flt3L treated Langerin-GFP mice per experiment.
Following size, live/dead, and exclusion criteria (CD3, CD19, NK1.1 exclusion) DC subsets
were sorted following the general gating schema depicted in S1a. DC-SIGN+ and CD205+
DC were sorted from the skin draining LNs of C57BL/6 mice 24 hours after intravenous
injection of 5ug of LPS (Cheong et al., 2010) and macrophages were isolated from
peritoneum.
Immunofluorescence
Back skin from Flt3L treated (12 days) or untreated C57BL/6 controls was isolated and
frozen in tissue-tek OCT (Sakura Finetek). 6-µm sections were cut by cryomicrotome
(Leica) sectioning, air-dried and fixed in ice-cold acetone. Sections were pre-treated with
endogenous avidin/biotin block (Invitrogen) and further blocked with 10% normal goat
serum (Jackson ImmunoResearch Laboratories). Sequential immunofluorescence staining
was performed using anti-langerin (clone 929F3, Dendritics), anti-CD11b (clone M1/70;
Biolegend) and anti-CD11c (clone HL3, BD Biosciences) with the appropriate secondary
antibodies (anti-rat IgG2a FITC (eBioscience), anti-rat IgG2b eFluor570 (eBioscience), and
streptavidin-Alexa Fluor 647 (Invitrogen). Sections were mounted with Vectashield with
DAPI (Vector labs). Images were acquired on a VS120 Whole Slide Scanner (Olympus) at
10X magnification using ASW software and analyzed using Olyvia software (Olympus).
Microarray analysis, normalization and data analysis
RNA samples were prepared by standard methods using Trizol (Invitrogen) and further
purified using RNeasy MinElute clean up (QIAGEN). Purity analysis was done by nanodrop
and Eukaryote Total RNA Pico Series II (Agilent). RNA was amplified and hybridized on
the Illumina MouseRef-8 v2.0 Expression BeadChip. For subset analysis at least three
replicates were analyzed from individual sorts to achieve statistical significance. Raw data
from Illumina single color chips were analyzed with GeneSpring 12.5. Intensities below
background were replaced with the average background over all samples. Quantile
normalization was applied to have a common distribution of intensities, followed by log2
transformation. Normalized values were baseline transformed to the median of all samples.
Normalized data were filtered to eliminate probes with low expression with a coefficient of
variation of less than 0.5 in population samples. One-way ANOVA was used to find
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Hochberg false discovery method set at p< 0.05). All DC subsets were arranged by a
hierarchical clustering algorithm using normalized intensity values and based on 2-fold
change or greater of all genes (n=8601). Heat maps for the differential expressions of core
DCs relative to macrophages (two-fold) were generated and analyzed (Figure 6C). For
selected DC genes of interest, heat maps were generated (Figure 6D) of normalized intensity
values.
Flow cytometry and gating
Cells were stained on ice in PBS with 2.0% (vol/vol) FCS. LSR II (Becton Dickinson) was
used for multiparametric flow cytometry of stained cell suspensions, followed by analysis
with FlowJo software (TreeStar).
Antibodies, live/dead dye, CFSE, FITC painting and staining reagents
The following reagents were from BD Biosciences, eBioscience or Biolegend: anti-Langerin
(eBioL31), anti-CD11c (N418), anti-CD4 (RM4-5), anti-CD8α (53-6.7), anti-CD11b
(M1/70), anti-CD103 (2E7), anti-Armenian Hamster IgG Isotype Control (eBio299Arm),
anti-rat IgG2a Isotype Control (eBR2a), anti-CD3 (500A2), anti-CD45 (30-F11), anti-
CD205 (NLDC-145), anti-EPCAM (G8.8), anti-CD24 (M1/69), anti-F4/80 (BM8), anti-
CD115 (AFS98), anti-PDCA1 (ebio927), anti-Ly6c (HK1.4), anti-B220 (RA3-6B2), anti-I-
A/I-E (M5/114.15.2), anti-CD3 (17A2), anti-CD19 (eBio1D3), anti-NK1.1 (PK136). AQUA
(L34957) was from Invitrogen. Cytofix/cytoperm kit was from BD Biosciences. CFSE was
from Sigma. Anti-CD205 (NLDC- 145) was produced in the Steinman lab and conjugated to
Alexafluor 488 or 647. Other reagents included PBS and FBS (Gibco-BRL), ACK lysing
buffer (BioSource). Staining with anti- Langerin and anti-CD205 was performed with cell
surface and intracellular label as described (Cheong et al., 2007). For intracellular blocking
2% rat serum was diluted into perm/wash buffer. All extracellular staining was performed in
ice cold PBS with 2% FCS. FITC painting was performed on the flank with 1:1 1% FITC in
acetone:Dibutyl phthalate (.5% FITC final) for 16–30 hours prior to harvest.
OVA presentation—Endotoxin free (< .001EU/µg) OVA was purchased from Hyglos.
For all groups, equal total numbers of DC subsets and CFSE labeled T cells were cultured at
a 1:10 ratio with increasing concentrations of soluble OVA protein.
MLR—Allo-MLR was performed as previously described (Anandasabapathy et al., 2011)
from FACS sorted LN resident and migDC subsets isolated from the skin draining LN.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Flt3L dependence of migratory DC subsets, including Langerin-CD11b− DC
A) Schema of LN DC from Flt3L-tumor treated vs. C57Bl/6 (B6) control mice at day 13. PDC (plasmacytoid DC), cDC
(classical LN resident DC), migDC (migratory DC) are labeled. (B) LN DC subsets Flt3L-treated (upper) vs. untreated
Langerin-GFP mice. (C) Quantitation of migratory DC from Flt3L-treated, control, Flt3L−/− mice (quantitated per skin draining
LN; error bars show mean +/− SD of 3 individual mice per group, analyzed by an unpaired t-test). (D) Flt3L-induced expansion
of skin resident DC subsets from "crawl-out” skin explants of doxycycline-inducible Flt3L mice given 8 days of doxycycline in
their drinking water (top) vs. untreated controls (bottom) (one representative experiment of two). (E) Quantitation of DC
isolated from skin explants “crawlouts” of Flt3L-treated vs. control Langerin GFP reporter mice (pooled from the ears of 3 mice
per experiment, one representative experiment of three). (F) α CD205+ staining of skin DC subsets from explant cultures of
doxycycline treated (Flt3L+) vs. untreated (control) mice (pooled from n=2 mice per condition).
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tFigure 2. CD11b− DC are skin-resident and migrate to the skin draining LN
(A) Upper: Representative skin draining LN DC gating from CCR7−/− mice treated with Flt3L (left), CCR7−/− untreated
controls (middle), and B6 controls (right). Lower: CCR7−/− skin resident DC subsets from “crawl-out” explants (Flt3L treated
vs. untreated controls). One of three representative experiments are shown. (B) FITC painting assay with gating on FITC+
migratory DC vs. total migratory DC in Flt3L treated (upper) and control mice (lower). CD11b− migDC (red) directly capture
FITC in the skin and traffic to the skin draining LN at 16 hour and 24 hours in C57BL6/WT mice (n=3 mice per time point). (C)
Immunofluorescence of flank sections of Flt3L-treated (upper) and control (lower) mice co-stained with langerin (green),
CD11b (red) and CD11c (magenta) and counterstained with DAPI to visualize cell nuclei. Positions of Langerhans cells (LC:
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tlangerin+, CD11b+, CD11c+, #). Dermal DC (CD11c+) were further distinguished as langerin-CD11b− (↑), langerin-CD11b+
(+) and langerin+CD11b− (*) were marked in the merged images. Scale bar =50 µm for all images.
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tFigure 3. Flt3L responsive CD11b− migDC include CD24high CX3CR1low subsets
(A) In skin and skin draining LN a subset of CD11b− migDC are CD24+ and expand with Flt3L. Gated pre (open) and post
(closed) Flt3L in LN and skin explant (lower) as compared to classical CD8α + DC and other migDC (n=3 mice per group, one
representative experiment of three). (B) Lower: Flt3L expanded CD24+ cells are CX3CR1low within the CD11b− migDC subset
(red) as compared to migratory CD11b+ cells (blue). Upper: Comparison of LN resident CD11b+ CD8α- cDC (blue) and CD8α
+ cDC which are CD24+ CX3CR1low (red) (n=2 Flt3L-treated or control CX3CR1 mice per group, one representative
experiment of two).
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tFigure 4. CD11b− migDC are Zbtb46 dependent
(A) LN classical vs. total migratory DC and (B) migratory DC subset counts from skin draining LNs after single dose DT vs.
PBS administration 24 or 48 hours prior to harvest (n=3 mice per time point, one representative experiment of three). (C) Skin
explants pooled from three Zbtb46DTR vs. C57BL/6 controls 24 hours after DT treatment (n=3 mice pooled per group, one
representative experiment of two).
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tFigure 5. CD11b− migDC present antigen
CD11b− migDC present antigen CD11b− migDC present allo-antigens in the mixed leukocyte reaction (A–B) and present OVA
protein (C–D) to CD8+ V α 2 OT-1 T cells wit equal efficiency to other DC subsets ex vivo. One of two duplicate experiments
are shown with triplicate wells per sample.
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tFigure 6. Langerin- CD11b− DC relate closely to classical DC
(A) Hierarchical clustering of subsets based on 2 fold change or greater of all genes (n=8601) (B) Heat map comparison of DC
signature gene expression across DC groups as compared to macrophages (yellow indicates the core DC signature). (C) Heat
map comparison of normalized intensity values from selected DC genes across all subsets.
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